# A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Source: https://onco.cc/trials/nct07060989/  
OnCo record `nct07060989` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of NTS071 in advanced solid tumours, run by Nutshell Therapeutics (Shanghai) Co., LTD., now recruiting.

## Summary

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation is a phase 1/2 interventional study registered as NCT07060989 by Nutshell Therapeutics (Shanghai) Co., LTD., with 220 participants planned, started 2025-08-04 and due to reach its primary completion in 2028-12. Interventions recorded: NTS071.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07060989
- Phase: 1/2
- Setting: A Phase 1/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
- Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT07060989: https://clinicaltrials.gov/study/NCT07060989

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07060989.json